跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 29 条关于
“Ibtrozi (taletrectinib)”
全部
29
临床试验
8
药物
1
机构
0
资讯
20
8个月前
Nuvation Bio's IBTROZI Demonstrates Strong Commercial Performance with 432 New Patients in First Six Months
前天
Taletrectinib Shows Consistent Efficacy Across ROS1+ NSCLC Subgroups Regardless of Prior Chemotherapy or Fusion Partner
2个月前
Nuvation Bio's David Hung on Building a Pipeline of Best-in-Class Oncology Drugs
昨天
FDA Approves Updated IBTROZI Label With Nearly 50-Month Duration of Response in TKI-Naive ROS1+ NSCLC
昨天
FDA Approves Taletrectinib Label Update Showing 49.7-Month Median Duration of Response in ROS1+ NSCLC
11个月前
Nuvation Bio Initiates Phase 3 Trial of Safusidenib for High-Grade IDH1-Mutant Glioma Maintenance Treatment
8个月前
Nuvation Bio Partners with Eisai in €195 Million Deal to Expand Taletrectinib Global Reach for ROS1+ NSCLC
9个月前
FDA Approves Five Novel Lung Cancer Therapies in 2025, Advancing Precision Medicine and Immunotherapy
去年
Innovent's Taletrectinib (DOVBLERON®) Receives Expanded Approval in China for ROS1-Positive NSCLC
去年
Nuvation Bio Secures $250M Financing for US Launch of ROS1 Inhibitor Taletrectinib
第 1 页,共 2 页
上一页
下一页